UK NEQAS Cardiac Markers

NHS Greater Glasgow & Clyde, operating UK NEQAS Cardiac Markers, is a UKAS accredited proficiency testing provider (No:8560)(BS EN ISO/IEC 17043:2010). We are a non-profit centre working within NHS Greater Glasgow and Clyde to improve cardiac biomarker investigations in the clinical laboratory sector for the benefit of patients.

Cardiac markers, especially Troponin I (cTnI) and Troponin T (cTnT), are critical measurements in acute coronary syndrome. Most authorities recommend that these measurements are carefully quality controlled. UKNEQAS Cardiac Marker schemes meet the external quality assessment (EQA) requirements of members by providing monthly distributions of samples with clinically relevant levels of these markers.

The scheme is a full member of UKNEQAS. The cardiac troponin EQA schemes have been in operation since 1998.

The following EQA schemes are all UKAS accredited:

Laboratory Based Schemes: cTnI (including high sensitivity methods), hsTnT, CKMB, Myoglobin, B-type Natriuretic Peptide (BNP) and NT-proB-type Natriuretic Peptide (NT-proBNP).
Point of Care Schemes - cTnI, cTnT, CKMB, Myoglobin, BNP and NT-proBNP.

The 4th Cardiac Marker Dialogues meeting took place in Glasgow on the 5th April 2019 with a record number of delegates. The 5th meeting is likely to be held in 2021. Information on the 2019 meeting is available on https://www.cmdmeeting.org.uk

UK NEQAS Cardiac Markers is operating normally. Distribution 266 for July 2020:

  • Samples will be dispatched to laboratories during the week beginning 29th of June.
  • Data entry for this distribution opens on the 6th July.
  • Final date for return of results 24th of July.

We will continue to review our dispatch dates over the next couple of months and adapt if required.

 

Where do you want to go?

 

Register to participate

 

General enquiry

Our Scope

Cardiac Markers

UK NEQAS Cardiac Markers is organised to provide a UK National External Quality Assessment Scheme for the assay of cardiac Troponin Iand Troponin T (including high sensitivity methods), Creatine Kinase (MB), Myoglobin, B-type Naturetic Peptide and N-Terminal -ProB-type Naturetic Peptide and will develop appropriate EQA schemes for new cardiac biomarkers. Schemes are available for both laboratory systems and for point of care systems.

 

Participation

Our schemes are open to all clinical/research laboratories in the UK and overseas. It is anticipated that the majority of participants will be UK NHS laboratories. The Scheme will accept participants from the private sector and from the diagnostics industry, within or out with theUK on the same basis (with fee adjustment) as UK laboratory participants.

Collaboration

We see it as part of the duty of an EQA scheme to give advice to participating laboratories about assay problems related to the EQA when this is asked for.  The EQA response to poor laboratory performance is separately described. We have contacts with developing cardiac Troponin EQA schemes in EU countries and elsewhere. We think it important to foster and contribute to these information links as there aresubstantial inter-assay calibration problems which still remain to be solved.


Register to Participate

 

If you do not participate at present and wish further information on the schemes we provide, contact us.

Latest News

NT-proBNP Commentary (Distribution 264)

As Abbott (calibrator product recall) and Siemens (method realignment) have or are making changes to their NT-proBNP methods I thought a short commentary on this analyte may be useful. This can be found at the end of your report for distribution 264.  Alan Reid (Scheme Organizer)

HEART Editorial: High-sensitivity cardiac troponin and the early rule out of myocardial infarction: time for action

Editorial from Andrew Chapman and Nick Mills View Article  

Troponins Touted as ‘Ally’ in COVID-19 Triage

Troponins Touted as ‘Ally’ in COVID-19 Triage.   https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047008  

See all our news